The National Heart, Lung, and Blood Institute (NHLBI) awarded a $874,792 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Vanderbilt University Medical Center (VUMC). The grant, awarded on July 15, 2024, will fund a 4-year research project focused on three key objectives: 1) Identifying new genetic factors associated with residual atherosclerotic cardiovascular disease (ASCVD) risk in patients on treatment to lower LDL-cholesterol and blood pressure; 2) Developing improved prediction models for residual ASCVD risk by leveraging electronic health records and machine learning; and 3) Conducting drug repurposing to identify new therapeutic options for reducing residual ASCVD risk. The project aims to address critical knowledge gaps in understanding the underlying mechanisms, risk factors, and treatment approaches for the substantial residual ASCVD burden experienced by many patients despite standard-of-care therapies.
Generated 3/4/25, 4:41 AM